Stocks and Investing
Stocks and Investing
Fri, April 16, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Brian Abrahams Maintained (VRTX) at Buy and Held Target at $265 on, Apr 16th, 2021
Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $265 on, Apr 16th, 2021.
Brian has made no other calls on VRTX in the last 4 months.
There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $251 on, Tuesday, January 19th, 2021
These are the ratings of the 4 analyists that currently disagree with Brian
- Brian Skorney of "Baird" Upgraded from Hold to Buy and Increased Target to $252 on, Tuesday, February 23rd, 2021
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021
Contributing Sources